Physician profile
David Adler
NPI 1588711386
$14,849.21
in general payments reported to CMS, 2019-2025
29 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,110 · 2020: $888 · 2021: $505 · 2022: $838 · 2023: $2,525 · 2024: $3,538 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,542 · Travel and Lodging: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.37 |
| Travel and Lodging | $1,965.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,902.64 | 2019-2025 | Mitraclip, Amplatzer Amulet, Navitor |
| Edwards Lifesciences Corporation | $3,121.76 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Evoque, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $2,709.10 | 2019-2025 | Opticross, Watchman Access System, S-Icd System Magnet |
| Medtronic, INC. | $1,110.46 | 2021-2025 | Corevalve Evolut R, Apollotm |
| Abiomed | $903.81 | 2019-2024 | Impella |
| Corindus INC. | $508.43 | 2019 | |
| Medtronic Vascular, INC. | $276.11 | 2019-2020 | |
| Biotronik INC. | $234.99 | 2019-2023 | Orsiro Mission |
| Philips North America LLC | $212.21 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.12 | 2019-2020 | |
| Zoll Circulation INC | $113.30 | 2025 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Regeneron Healthcare Solutions, INC. | $111.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.66 | 2019 | |
| Cardiovascular Systems INC. | $66.34 | 2019-2023 | Diamondback Coronary |
| Janssen Scientific Affairs, LLC | $59.81 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.70 | 2019 | |
| Astellas Pharma US INC | $40.78 | 2019 | |
| Pfizer INC. | $38.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.42 | 2019 | |
| Lilly USA, LLC | $18.12 | 2022 | |
| Nuwellis, INC. | $16.48 | 2019 | |
| Irhythm Technologies, INC. | $15.02 | 2019 | |
| Smith+Nephew, INC. | $14.79 | 2019 | |
| Chiesi USA, INC. | $14.05 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $13.22 | 2019 | |
| Amgen INC. | $12.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.